Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hightide Therapeutics Inc ( (HK:2511) ) has shared an update.
HighTide Therapeutics has appointed veteran finance and tax expert Chen Mingyu as an independent non-executive director, chairman of the audit committee and member of the remuneration committee, effective May 4, 2026. Chen brings more than 35 years of international experience, including senior roles at Deloitte, Ernst & Young and KPMG, as well as board and audit committee leadership positions at several listed companies across Hong Kong, mainland China and Singapore.
Under a three-year renewable term, Chen will receive annual remuneration of HKD200,000, set with reference to his duties and market benchmarks for similar listed companies. The company emphasized his independence, noting he holds no shares, relationships or conflicting interests with HighTide, and his appointment is expected to strengthen the group’s financial oversight, risk management and corporate governance as it expands in global markets.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is a biopharmaceutical company listed on the Hong Kong Stock Exchange that operates through subsidiaries as a group. The company focuses on developing and commercializing therapeutics, leveraging international governance standards and maintaining a board structure with independent non-executive directors and specialized committees such as audit and remuneration.
Average Trading Volume: 1,039,879
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$1.95B
Learn more about 2511 stock on TipRanks’ Stock Analysis page.